StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) company profile

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.99−0.01 (-0.25%)

Close on Nov 18, 2026Market cap $1.30BP/E –Yield –

About Taysha Gene Therapies

Biological Products, (No Diagnostic Substances), SIC 2836

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company that develops adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical development program is TSHA-102, an investigational gene therapy for the treatment of females with Rett syndrome caused by MECP2 loss-of-function mutations. The company focuses on developing transformative treatments to serve patients suffering from severe monogenic central nervous system disorders and their caregivers.

The company operates clinical trial programs across the United States and Canada, evaluating adolescent, adult, and pediatric participant cohorts in its ongoing studies. Taysha Gene Therapies maintains its principal executive offices in Dallas, Texas.

Summary of the business section of Taysha Gene Therapies's latest annual report, written by StockData.

Company profile

Company

Legal name
Taysha Gene Therapies, Inc.
Headquarters
Dallas, TX
Address
3000 Pegasus Park Drive, Suite 1430 75247
Phone
(214) 612-0000
Employees
99, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Chicago, IL

Stock & identifiers

Ticker
TSHA
Exchange
Nasdaq
IPO date
Sep 25, 2020
Shares outstanding
326M, Aug 11, 2026
Public float
$544.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1806310
CUSIP
877619106
ISIN
US8776191061
FIGI
BBG00TJXFDP1
Share class FIGI
BBG00TJXFDQ0
EIN
84-3199512

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sukumar NagendranPresident and Head of R&D, Director936,410
Sean P. NolanChief Executive Officer, Director4,443,802
Kamran AlamCHIEF FINANCIAL OFFICER1,442,131
Laura Sepp-LorenzinoDirector127,178
Alison S. LongDirector127,178
Phillip B. DonenbergDirector241,289
John A. Stalfort IIIDirector2,060,849

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.10M$18.26M$2.12M$311–
FY2024$4.73M$4.67M$3.06M$98–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Sean Nolan
Chief Executive Officer and Director
$645.84K$1.65M$1.26M$542.51K$1.17K$4.10M-13%
Kamran Alam
Chief Financial Officer
$473.33K$797.35K$607.71K$265.07K$3.51K$2.15M-15%
Sukumar Nagendran, M.D.
President and Head of Research and Development and Director
$608.17K$600.33K$457.55K$425.72K$1.14K$2.09M-42%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 25, 2020
Offer price
$20.00
Securities offered
7,869,566
Gross proceeds
$157.39M
Exchange
Nasdaq
First trading day
Sep 24, 2020
First-day close
$24.06+20.3%
Lock-up ends (est.)
Mar 23, 2021

“The initial public offering price per share of our common stock is $20.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 99 employees, all of whom were full-time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?